Cryo-Cell International (NYSEAMERICAN:CCEL) Posts Quarterly Earnings Results

Cryo-Cell International (NYSEAMERICAN:CCEL) posted its earnings results on Wednesday. The company reported $0.07 EPS for the quarter, FiscalAI reports. The firm had revenue of $7.78 million during the quarter.

Cryo-Cell International Stock Performance

Shares of NYSEAMERICAN:CCEL opened at $3.48 on Friday. The company has a market capitalization of $28.05 million, a PE ratio of -11.60 and a beta of 0.49. The stock has a fifty day moving average of $3.52 and a 200-day moving average of $3.45. Cryo-Cell International has a one year low of $2.72 and a one year high of $5.43.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Cryo-Cell International stock. Susquehanna International Group LLP acquired a new position in shares of Cryo-Cell International Inc. (NYSEAMERICAN:CCEL) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 11,062 shares of the company’s stock, valued at approximately $51,000. Susquehanna International Group LLP owned approximately 0.14% of Cryo-Cell International as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 10.44% of the company’s stock.

Cryo-Cell International Company Profile

Cryo-Cell International, Inc is a pioneering provider of umbilical cord blood and tissue preservation services. Headquartered in Oldsmar, Florida, the company was founded in 1989 as the first private cord blood bank in the United States. Cryo-Cell operates FDA-registered and AABB-accredited laboratory facilities, maintaining stringent quality control measures and cryogenic storage systems to safeguard stem cell viability over long-term storage periods.

The company’s primary business activity centers on the collection, processing and secure storage of newborn stem cell sources harvested at birth.